Literature DB >> 29725415

The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Lei Wu1,2,3, Lili Yang1,2,3.   

Abstract

As a non-histone chromatin-associated protein, high-mobility group box-1 (HMGB1) performs a pivotal function in various human diseases, including autoimmune diseases, neurodegenerative diseases and cancer. Overexpression of HMGB1 has been demonstrated in numerous types of cancer, including breast cancer, colorectal cancer, lung cancer and hepatocellular carcinoma. However, the underlying mechanism of HMGB1 function in lung cancer remains to be elucidated. The present study aimed to analyze, and summarize the role and mechanism of HMGB1 in lung cancer by retrieving available literature regarding HMGB1 in association with lung cancer. It provides comprehensive information on the association of HMGB1 with the carcinogenesis and progression of lung cancer, and discusses the molecular mechanism of these processes. HMGB1 may induce tumorigenesis, metastasis and chemotherapy resistance in lung cancer. Overall, it is evident that HMGB1 serves an important role in the development and progression of lung cancer, and this review warrants further investigation into HMGB1 as a novel target for cancer therapy.

Entities:  

Keywords:  function; high-mobility group protein B1; lung cancer; proliferation

Year:  2018        PMID: 29725415      PMCID: PMC5920474          DOI: 10.3892/ol.2018.8215

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  90 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

Review 3.  The functions of HMGB1 depend on molecular localization and post-translational modifications.

Authors:  U Andersson; D J Antoine; K J Tracey
Journal:  J Intern Med       Date:  2014-11       Impact factor: 8.989

4.  MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1.

Authors:  Yun Liu; Xu Hu; Daokui Xia; Songlin Zhang
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

5.  HMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2.

Authors:  Yue Liang; Changchun Hou; Jinliang Kong; Hanchun Wen; Xiaowen Zheng; Lihong Wu; Hong Huang; Yiqiang Chen
Journal:  Mol Cell Biochem       Date:  2015-04-11       Impact factor: 3.396

6.  HMGB1: a novel Beclin 1-binding protein active in autophagy.

Authors:  Rui Kang; Kristen M Livesey; Herbert J Zeh; Michael T Loze; Daolin Tang
Journal:  Autophagy       Date:  2010-11-16       Impact factor: 16.016

7.  HMGB1 modulates Lewis cell autophagy and promotes cell survival via RAGE-HMGB1-Erk1/2 positive feedback during nutrient depletion.

Authors:  Zhaoliang Su; Ting Wang; Haitao Zhu; Pan Zhang; Rongxia Han; Yueqin Liu; Ping Ni; Huiling Shen; Wenlin Xu; Huaxi Xu
Journal:  Immunobiology       Date:  2014-12-30       Impact factor: 3.144

8.  Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage.

Authors:  Natalia F Krynetskaia; Manali S Phadke; Sachin H Jadhav; Evgeny Y Krynetskiy
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells.

Authors:  Laura Conti; Stefania Lanzardo; Maddalena Arigoni; Roberta Antonazzo; Enrico Radaelli; Daniela Cantarella; Raffaele A Calogero; Federica Cavallo
Journal:  FASEB J       Date:  2013-08-22       Impact factor: 5.191

View more
  26 in total

Review 1.  Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways.

Authors:  Xiangning Bu; Jiro Kato; Joel Moss
Journal:  Biochem Pharmacol       Date:  2018-09-27       Impact factor: 5.858

Review 2.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

3.  Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming.

Authors:  Samantha M Morrissey; Fan Zhang; Chuanlin Ding; Diego Elias Montoya-Durango; Xiaoling Hu; Chenghui Yang; Zhen Wang; Fang Yuan; Matthew Fox; Huang-Ge Zhang; Haixun Guo; David Tieri; Maiying Kong; Corey T Watson; Robert A Mitchell; Xiang Zhang; Kelly M McMasters; Jian Huang; Jun Yan
Journal:  Cell Metab       Date:  2021-09-23       Impact factor: 31.373

4.  Downregulation of high mobility group box 1 enhances the radiosensitivity of non-small cell lung cancer by acting as a crucial target of microRNA-107.

Authors:  Lu Bai; Jingjing Zhang; Dongqi Gao; Chengyi Liu; Wenxin Li; Qingshan Li
Journal:  Exp Ther Med       Date:  2021-04-25       Impact factor: 2.447

Review 5.  High Mobility Group Box 1 in Human Cancer.

Authors:  Bernardo L Rapoport; Helen C Steel; Annette J Theron; Liezl Heyman; Teresa Smit; Yastira Ramdas; Ronald Anderson
Journal:  Cells       Date:  2020-07-10       Impact factor: 6.600

6.  Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells.

Authors:  Mana Inada; Mika Shindo; Kyousuke Kobayashi; Akira Sato; Yohei Yamamoto; Yasuharu Akasaki; Koichi Ichimura; Sei-Ichi Tanuma
Journal:  PLoS One       Date:  2019-05-17       Impact factor: 3.240

Review 7.  AGE-RAGE synergy influences programmed cell death signaling to promote cancer.

Authors:  Bhargav N Waghela; Foram U Vaidya; Kishu Ranjan; Abu Sufiyan Chhipa; Budhi Sagar Tiwari; Chandramani Pathak
Journal:  Mol Cell Biochem       Date:  2020-10-06       Impact factor: 3.396

Review 8.  Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified.

Authors:  Mehrdad Nasrollahzadeh Sabet; Masood Movahedi Asl; Mahtab Kazemi Esfeh; Navid Nasrabadi; Maryam Shakarami; Behrang Alani; Asma Alimolaie; Sara Azhdari; Ebrahim Cheraghi
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

9.  Inflammation during Lung Cancer Progression and Ethyl Pyruvate Treatment Observed by Pulmonary Functional Hyperpolarized 129Xe MRI in Mice.

Authors:  Atsuomi Kimura; Seiya Utsumi; Akihiro Shimokawa; Renya Nishimori; Neil J Stewart; Yoshihiro Kamada; Hirohiko Imai; Hideaki Fujiwara
Journal:  Contrast Media Mol Imaging       Date:  2021-06-28       Impact factor: 3.161

10.  microRNA-505 negatively regulates HMGB1 to suppress cell proliferation in renal cell carcinoma.

Authors:  Bing Zhong; Zhiqiang Qin; Hui Zhou; Fengming Yang; Ke Wei; Xi Jiang; Ruipeng Jia
Journal:  J Cell Physiol       Date:  2019-01-15       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.